Malignant Intracranial Neoplasm — Trials

Malignant Intracranial Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

637 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 192
Recruiting: 110
Ph III recruiting: 4
Growth YoY: +6.3%
Industry share: 10%
Top sponsor: National Cancer Institute (NCI)
Termination share: 39.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (100)

clinicaltrialsPublishedShowing 1–12 of 12 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06466798	Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies	withdrawn	Phase 1	0	Jeffrey TreiberOTHER	0	Jan 8, 2026	clinicaltrials
NCT05457959	Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant	withdrawn	Phase 1	0	Jonsson Comprehensive Cancer CenterOTHER	1